Overview

The Company’s current research and development pipeline includes two products based on the novel natural oestrogen Estetrol (E4) as well as three complex generic products.

Further information will be available in the prospectus on the Investors website.

Estetrol

Pre-clinical
Phase I
Phase II
Phase III
Registration

Oral contraceptive

Estelle®

HRT-VMS

Donesta®

Complex Generics

2014
2015
2016
2017
2018

Tibelia®

2.5 mg

Zoreline®*

3.6 mg: PD & PK studies
10.8 mg: PD & PK studies

MyRing®*

Formulation development | Bioequivalence

| Dossier Submission

 Expected Approval

*  Development by Novalon